Is India forever a generics-only player?
When the Indian Patent Office rejected multinational conglomerate (MNC) AbbVie’s patent application for its cancer drug Venetoclax in late January, there was customary cheerleading that follows such decisions. Drug companies here were happy because their patent opposition, filed over a seven-year period from 2018, had finally been upheld and allowed them to launch generic versions […]
Is India forever a generics-only player? Read More »








